<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634034</url>
  </required_header>
  <id_info>
    <org_study_id>NK-104-CR-1.01US</org_study_id>
    <nct_id>NCT02634034</nct_id>
  </id_info>
  <brief_title>A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics and safety of a controlled
      release (CR) version of pitavastatin (also referred to as NK-104) to immediate release (IR)
      pitavastatin in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>0 to 48 hours</time_frame>
    <description>Area Under the Curve 0 to tau</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A: NK-104-CR 8 mg</intervention_name>
    <description>NK-104-CR 8 mg (Controlled Release single 8-mg tablet)</description>
    <arm_group_label>NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)</arm_group_label>
    <arm_group_label>Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)</arm_group_label>
    <arm_group_label>Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: Pitavastatin IR 4 mg</intervention_name>
    <description>Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)</description>
    <arm_group_label>NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)</arm_group_label>
    <arm_group_label>Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)</arm_group_label>
    <arm_group_label>Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C: Pitavastatin IR 8 mg</intervention_name>
    <description>Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)</description>
    <arm_group_label>NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)</arm_group_label>
    <arm_group_label>Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)</arm_group_label>
    <arm_group_label>Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject provides written informed consent before any study-specific evaluation is
             performed.

          -  Subject is a healthy adult male or female volunteer between the ages of 18 and 45
             years, inclusive.

          -  Subject has no clinically significant abnormalities on the basis of medical history,
             physical examination findings, or vital sign measurements, as judged by the
             Investigator.

          -  Subject is able and willing to comply with the protocol and study procedures.

        Exclusion Criteria:

          -  Subject is a woman who is pregnant or breastfeeding.

          -  Subject has clinically relevant abnormalities in the screening or check-in
             assessments.

          -  Subject has received an investigational drug within 30 days before the first dose of
             study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>January 8, 2016</last_update_submitted>
  <last_update_submitted_qc>January 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

